Philips and Merck Partnership: To Advance Personalized Fertility Treatment

Royal Philips, a global leader in health technology, today announced a multi-year partnership with Merck, a leading science and technology company, to develop clinical-grade digital solutions for highly personalized fertility treatment.

Leveraging digital health technologies, advanced informatics, and mobile, AI-enabled ultrasound diagnostics, these solutions will aim to better inform patients and clinicians about the choice and timing of fertility treatment to maximize the chances of conception. 

“At Philips we are leading digital transformation in healthcare, with a portfolio that includes solutions for both professionals and consumers to support parents-to-be through pregnancy and the first years of their baby’s life,” said Jeroen Tas, Chief Innovation & Strategy Officer, Royal Philips. “The journey for aspiring parents is sometimes a difficult one, and by collaborating with Merck, a world leader in fertility treatment, we aim to develop integrated digital solutions that improve the patient experience and can ultimately have a positive impact on health outcomes. This partnership builds on our expertise in maternal and fetal monitoring, our Pregnancy+ and Baby+ consumer engagement apps, our leading ultrasound solutions and our HealthSuite Cloud/AI platform.” 

“We believe that the future of IVF will be unlocked through digital health technologies that empower professionals and patients to be better connected,” said Michelangelo Canzoneri, Global Head of Digital and Data, Healthcare at Merck. “With Philips, we have a partner that shares our belief in the potential of digital health to improve the patient experience, bringing a wealth of experience in connected care to our offering. Together, this collaboration will push our two companies to think beyond tomorrow and discover new solutions that can empower people to realize their dreams of parenthood,” added Jan Kirsten, Head of Global Business Franchise for Fertility at Merck.

Digital health and virtual care technologies have proved invaluable during the COVID-19 pandemic in keeping patients and their care teams in virtual contact, accelerating digital transformation in healthcare. Digital technologies including remote patient monitoring, cloud-based services and AI are playing an ever more important part in achieving better patient outcomes, better patient and staff experiences, and low cost of care – the quadruple aim of healthcare.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version